204656-20-2

Liraglutide (Liraglutida) is a synthetic analog of glucagon-like peptide-1 (GLP-1), an agonist of the GLP-1 receptor. Liraglutide can be used to treat type 2 diabetes and chronic obesity.

Liraglutide-D8 tetraTFA is the deuterated form of Liraglutide. Liraglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist and is utilized in the study of type 2 diabetes.

Liraglutide-13C5,15N trifluoroacetic acid is a version of Liraglutide labeled with 13C and 15N isotopes. Liraglutide trifluoroacetic acid (T6876) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is clinically used for the treatment of type 2 diabetes.

Liraglutide acetate is the acetate salt form of Liraglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist, utilized in the study of type 2 diabetes.

Liraglutide (TFA) is an agonist of the glucagon-like peptide 1 receptor (GLP-1). It activates GLP-1, leading to insulin secretion when glucose levels are elevated. Additionally, Liraglutide (TFA) reduces glucagon secretion in a glucose-dependent manner. This compound is utilized in research related to type 2 diabetes.

Liraglutide-13C6,15N trifluoroacetic acid is a version of Liraglutide labeled with 13C and 15N. Liraglutide trifluoroacetic acid (T6876) acts as a glucagon-like peptide-1 (GLP-1) receptor agonist and is clinically used for the treatment of type 2 diabetes.